Cytek Biosciences (CTKB) Net Cash Flow (2020 - 2026)

Cytek Biosciences has reported Net Cash Flow for 7 years, with the latest figure at -$25.8 million in Q1 2026.

• For the quarter ending Q1 2026, Net Cash Flow fell 1064.74% year-over-year to -$25.8 million; the trailing twelve-month figure through Mar 2026 stood at -$31.6 million (up 58.1% YoY), and the FY2025 full-year result was -$8.0 million, up 89.1% from the prior year.
• Net Cash Flow for Q1 2026 stood at -$25.8 million, down from -$3.8 million in the prior quarter.
• The five-year high for Net Cash Flow was $30.6 million in Q3 2023, with the low at -$166.0 million in Q1 2023.
• Historically, Net Cash Flow has averaged -$17.7 million across 5 years, with a median of -$3.8 million in 2025.
• Annual changes were most pronounced in 2023 — Net Cash Flow plunged 8656.12% — and 2024, when it jumped 4076.28%.
• Cytek Biosciences' Net Cash Flow stood at -$41.0 million in 2022, then jumped by 111.76% to $4.8 million in 2023, then tumbled by 1449.0% to -$65.1 million in 2024, then jumped by 94.1% to -$3.8 million in 2025, then sank by 572.94% to -$25.8 million in 2026.
• The last three Net Cash Flow figures came in at -$25.8 million (Q1 2026), -$3.8 million (Q4 2025), and $17.0 million (Q3 2025), per Business Quant data.